Tech rivals Apple and Samsung are continuing their feud over alleged patent infringement, with the latest development seeing Apple appeal an earlier ruling that denied the iPhone maker’s request for Samsung smartphone sale bans.
Reports say Apple has filed an appeal of US District Judge Lucy Koh’s decision, made for a second time earlier this month, to reject Apple’s request to ban sales of more than 20 Samsung smartphones – none of which are still on the market – for allegations Samsung infringed on Apple patents. Apple has now asked the US Court of Appeals for the Federal Circuit in Washington to review the case, say reports.
The appeal is just next chapter in the saga of intellectual property disputes between the companies. Another trial is set to begin next month regarding newer smartphone devices, say reports.
Experts say Judge Koh’s ruling may also boost Samsung’s chances of eventually settling the matter.
Samsung launched its own attack against Apple for patent infringement, winning an import ban on some Apple products found to have violated Samsung patents, a decision that was eventually overturned.
Reports say the companies have spent hundreds of millions of dollars on legal attacks against each other for alleged patent infringement since 2011.
Both rivals face new lawsuit
The news of Apple’s appeal follows reports say tech firm ZiiLabs has sued both Samsung and Apple of patent infringement.
ZiiLabs, which is owned by Creative Technology, reportedly filed the suit in Texas against the companies for violating smartphone, tablet and laptop patents.
Reports say Samsung Galaxy phones, tablets and laptops, in addition to Apple iPhones, iPads and computers, infringed on 10 ZiiLab patents regarding video streaming and other technologies.
Full Content: Bloomberg and Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas